DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

NCT03505710 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

181

Enrollment

INDUSTRY

Sponsor class

Stopped Last participant transitioned to alternative study.

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Trastuzumab deruxtecan

Sponsor

Daiichi Sankyo

Collaborators

[object Object]
[object Object]